Month: January 2017

Exactech Announces Divestiture of Spine Assets and Restructuring Charges

Gainesville, Fla. (Jan. 31, 2017) – With the goals of increasing productivity, enhancing profitability of its worldwide business, and strengthening its focus on core competencies, Exactech, (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for extremities, hip, knee and spine, has announced the restructuring of its Spine and Biologics business segment including the divestiture of its spine products business and restructuring charges related to international operations. The divestiture was executed through a spine asset sale today to ChoiceSpine, a private enterprise headquartered in Knoxville, Tenn.  Terms of the transaction were not released.

Exactech CEO David Petty said, “For nearly a decade, Exactech has driven innovations in spinal surgery and we are pleased to have made meaningful contributions to patient care.  We are confident the transfer of these products to ChoiceSpine will provide a continued focus on improving patient care for that population. This divestiture will allow us to sharpen our focus on investments in the core extremities and large joint segments of our business.”

According to Martin Altshuler, who co-founded ChoiceSpine with Rick Henson, “The additional technologies that Exactech has access to, combined with our expanding portfolio, allows us to further solidify our company as a premier, full-line spinal fusion provider in the U.S., with further growth opportunities in select international markets,” said Altshuler.

“We’re now in a position to dive deeper into our growth strategy by adding and introducing new distribution and surgeon users to our current and future technologies that we plan to launch over the next few months,” added Henson.

Exactech stated that the restructuring initiative and losses on the impairment of Spine and Biologics assets, including goodwill and spine assets sold, will result in a pre-tax charge to 2016 earnings in the range of $15-17 million. Looking ahead, the company expects 2017 revenue to be in the range of $264 – $272 million and earnings per share to be in the range of $1.24 to $1.32.

Earnings for 2016 will be released on Tuesday, Feb. 21, 2017 before market open, and additional restructuring details will be reviewed during the company’s 2016 year-end earnings call on Tuesday, Feb. 21, 2017 at 10 a.m. EST.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at and

A current investment profile on Exactech (Nasdaq: EXAC) is available online at To receive future releases in email alerts, sign up at

About ChoiceSpine

ChoiceSpine is a privately held spinal implant company located in Knoxville, Tenn., and prides itself on providing excellent products and exceptional service to meet the needs of their customers.  ChoiceSpine offers a breadth of innovative and surgeon focused systems that are designed to be safe, efficient, and easy-to-use. By working closely with physicians and maintaining service-focused distribution, ChoiceSpine will continue to bring technically-superior spinal products to the market.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

Investor contacts 

Jody Phillips
Executive Vice President of Finance & Chief Financial Officer

Julie Marshall or Frank Hawkins
Hawk Associates

Media contact

Priscilla Bennett
Vice President, Corporate & Marketing Communication

Anderson Collins
Business Development, ChoiceSpine, LP

Does Post-Op Protocol Affect Function and Pain After TSA?

Felix  Savoie, MD

Read complete study: Immediate versus delayed passive range of motion following total shoulder arthroplasty 

A recent article from Denard and Ladermann looked at the difference in ROM, VAS pain scores and ASES scores between differing post-op protocols of immediate motion and delayed motion.

The immediate motion group wore a sling for four weeks following surgeries; passive forward flexion and passive external rotation of the shoulder joint was started on day one post-op. Active hand, wrist and elbow exercise and active scapular retraction were allowed immediately as well. At four weeks, the sling was discontinued and passive external rotation was allowed as tolerated. Strengthening was initiated routinely at eight weeks post-op.

In the delayed motion group, a sling was worn for four weeks following surgery. During these four weeks, patients only performed active hand, wrist and elbow exercises, as well as scapular retraction exercises. At four weeks, the sling was discontinued and passive forward elevation and external rotation was allowed as tolerated. At eight weeks post-op, active assisted progression to active ROM was allowed and strengthening was routinely started. Activities were allowed as tolerated at 16 weeks post-op with a lifetime recommendation of no overhead lifting of 25lbs or more.

The findings of the article showed that at one-year post-op there was no difference between the two groups in ROM, ASES and VAS pain. An interesting finding in this paper was that the immediate motion group had a higher failure rate of the tuberosity osteotomy used to repair the subscapularis. The authors point out that immediate motion group saw initial improvements in ROM, but after three months both groups had relatively the same ROM. The benefit of early motion may not outweigh the risk of the subscap failure, which in my opinion, is a major risk of total shoulder arthroplasty.

I also employ a subscapularis sparing technique on high-demand younger patients where early motion is achievable and risk to the subscapularis is minimal.

My current post-op protocol is to protect the subscapularis for approximately six weeks if I have to detach it. I usually use a thin LT osteotomy,  but I also employ a subscapularis sparing technique on high-demand younger patients where early motion is achievable and risk to the subscapularis is minimal. The technique uses a modified technique through the delto-pectoral approach approximately 50 percent of the inferior subscapularis is taken down while keeping the top 50 percent attached.